Article Text
PDF
Abstract
Objectives To determine the distribution of prostate cancer (PCa) patients between physical activity and kinesiophobia, fatigue and quality of life, and to what extent PCa persists compared to healthy males.
Methods Total of 118 males participated in the study. These participants were allocated into two groups: PCa group (n:59) and control group (n:59). The International Physical Activity Questionnaire Short Form was used to assess physical activity levels, Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire (FACIT-F) was used for measuring fatigue, kinesiophobia was evaluated with the Kinesiophobia Causes Scale, and Functional Assessment of Cancer Treatment-Prostate Version questionnaire (FACT-P) was used to assess quality of life.
Results PCa had significantly lower scores in moderate activity (p=0.005) and total physical activity (p=0.010) compared with the control. Scores for kinesiophobia in both biological (p=0.045) and psychological subparameters (p=0.001), as well as the total kinesiophobia score (p=0.003), were higher in PCa. The FACIT-F (p<0.001) and total FACT-P (p<0.001) score were significantly lower in PCa than the control.
Conclusion Kinesiophobia in PCa is significantly influenced by both biological and psychological factors. Kinesiophobia negatively affects patients’ functional status and overall quality of life. Their well-being is shaped not only by their physical and emotional conditions but also by the quality of their family relationships. This multifaceted impact highlights the complex interaction between physical activity, functional abilities, emotional health and social dynamics in PCa. In addition to routine treatments for PCa patients, the development and implementation of a comprehensive rehabilitation programme may lead to significant improvements in their quality of life.
- Quality of life
- Prostate
- Survivorship
- Fatigue
Data availability statement
Data may be obtained from a third party and are not publicly available. The deidentified data we analysed are not publicly available, but requests to the corresponding author for the data will be considered on a case-by-case basis.
Statistics from Altmetric.com
Data availability statement
Data may be obtained from a third party and are not publicly available. The deidentified data we analysed are not publicly available, but requests to the corresponding author for the data will be considered on a case-by-case basis.
Footnotes
Contributors EC is the guarantor of the study, responsible for the integrity of the work as a whole, from its inception to the published article. Project conceptualisation and design: EC; methodology: all authors; formal analysis: CSP; resources: all authors; writing–original draft: EC, CSP, IK and OFC; writing review and editing: all authors; supervision: GK, AA and YEG. In my work, I used an AI-powered tool for some text translations and critiques. This helped speed up the process and improve accuracy.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Author note I utilized an AI tool for the translation process. This was intended to improve clarity and ensure the accurate translation of specific terms. I value transparency in this process and want to comply with the journal's requirements.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.